BACKGROUND: Myocardial energy metabolism is a strong predictor of postoperative cardiac function. This study profiled the metabolites and metabolic changes in the myocardium exposed to sevoflurane, propofol, and Intralipid and investigated the underlying molecular mechanisms. METHODS: Sevoflurane (2 vol%) and propofol (10 and 100 microM) in the formulation of 1% Diprivan (AstraZeneca Inc., Mississauga, ON, Canada) were compared for their effects on oxidative energy metabolism and contractility in the isolated working rat heart model. Intralipid served as a control. Substrate flux through the major pathways for adenosine triphosphate generation in the heart, that is, fatty acid and glucose oxidation, was measured using [H]palmitate and [C]glucose. Biochemical analyses of nucleotides, acyl-CoAs, ceramides, and 32 acylcarnitine species were used to profile individual metabolites. Lipid rafts were isolated and used for Western blotting of the plasma membrane transporters CD36 and glucose transporter 4. RESULTS: Metabolic profiling of the hearts exposed to sevoflurane and propofol revealed distinct regulation of fatty acid and glucose oxidation. Sevoflurane selectively decreased fatty acid oxidation, which was closely related to a marked reduction in left ventricular work. In contrast, propofol at 100 microM but not 10 microM increased glucose oxidation without affecting cardiac work. Sevoflurane decreased fatty acid transporter CD36 in lipid rafts/caveolae, whereas high propofol increased pyruvate dehydrogenase activity without affecting glucose transporter 4, providing mechanisms for the fuel shifts in energy metabolism. Propofol increased ceramide formation, and Intralipid increased hydroxy acylcarnitine species. CONCLUSIONS: Anesthetics and their solvents elicit distinct metabolic profiles in the myocardium, which may have clinical implications for the already jeopardized diseased heart.
BACKGROUND: Myocardial energy metabolism is a strong predictor of postoperative cardiac function. This study profiled the metabolites and metabolic changes in the myocardium exposed to sevoflurane, propofol, and Intralipid and investigated the underlying molecular mechanisms. METHODS:Sevoflurane (2 vol%) and propofol (10 and 100 microM) in the formulation of 1% Diprivan (AstraZeneca Inc., Mississauga, ON, Canada) were compared for their effects on oxidative energy metabolism and contractility in the isolated working rat heart model. Intralipid served as a control. Substrate flux through the major pathways for adenosine triphosphate generation in the heart, that is, fatty acid and glucose oxidation, was measured using [H]palmitate and [C]glucose. Biochemical analyses of nucleotides, acyl-CoAs, ceramides, and 32 acylcarnitine species were used to profile individual metabolites. Lipid rafts were isolated and used for Western blotting of the plasma membrane transporters CD36 and glucose transporter 4. RESULTS: Metabolic profiling of the hearts exposed to sevoflurane and propofol revealed distinct regulation of fatty acid and glucose oxidation. Sevoflurane selectively decreased fatty acid oxidation, which was closely related to a marked reduction in left ventricular work. In contrast, propofol at 100 microM but not 10 microM increased glucose oxidation without affecting cardiac work. Sevoflurane decreased fatty acid transporter CD36 in lipid rafts/caveolae, whereas high propofol increased pyruvate dehydrogenase activity without affecting glucose transporter 4, providing mechanisms for the fuel shifts in energy metabolism. Propofol increased ceramide formation, and Intralipid increased hydroxy acylcarnitine species. CONCLUSIONS: Anesthetics and their solvents elicit distinct metabolic profiles in the myocardium, which may have clinical implications for the already jeopardized diseased heart.
Authors: Sudeepa Bhattacharyya; Mohamed Ali; William H Smith; Paul E Minkler; Maria S Stoll; Charles L Hoppel; Sean H Adams Journal: Am J Physiol Endocrinol Metab Date: 2017-08-22 Impact factor: 4.310
Authors: Masaki Kajimoto; Douglas B Atkinson; Dolena R Ledee; Ernst-Bernhard Kayser; Phil G Morgan; Margaret M Sedensky; Nancy G Isern; Christine Des Rosiers; Michael A Portman Journal: J Cereb Blood Flow Metab Date: 2014-01-08 Impact factor: 6.200
Authors: Vineet K Singh; Sirisha Sirobhushanam; Robert P Ring; Saumya Singh; Craig Gatto; Brian J Wilkinson Journal: J Med Microbiol Date: 2018-03-02 Impact factor: 2.472
Authors: K J Grim; A J Abcejo; A Barnes; V Sathish; D F Smelter; G C Ford; M A Thompson; Y S Prakash; C M Pabelick Journal: Br J Anaesth Date: 2012-04-27 Impact factor: 9.166
Authors: Blair E Warren; Phing-How Lou; Eliana Lucchinetti; Liyan Zhang; Alexander S Clanachan; Andreas Affolter; Martin Hersberger; Michael Zaugg; Hélène Lemieux Journal: Am J Physiol Endocrinol Metab Date: 2014-01-14 Impact factor: 4.310
Authors: Phing-How Lou; Eliana Lucchinetti; Liyan Zhang; Andreas Affolter; Manoj Gandhi; Martin Hersberger; Blair E Warren; Hélène Lemieux; Hany F Sobhi; Alexander S Clanachan; Michael Zaugg Journal: PLoS One Date: 2014-08-15 Impact factor: 3.240
Authors: Jake Russell; Eugene F Du Toit; Jason N Peart; Hemal H Patel; John P Headrick Journal: Cardiovasc Diabetol Date: 2017-12-04 Impact factor: 9.951
Authors: Charissa E van den Brom; Carolien Se Bulte; Stephan A Loer; R Arthur Bouwman; Christa Boer Journal: Cardiovasc Diabetol Date: 2013-03-04 Impact factor: 9.951
Authors: Phing-How Lou; Eliana Lucchinetti; Liyan Zhang; Andreas Affolter; Marcus C Schaub; Manoj Gandhi; Martin Hersberger; Blair E Warren; Hélène Lemieux; Hany F Sobhi; Alexander S Clanachan; Michael Zaugg Journal: PLoS One Date: 2014-01-30 Impact factor: 3.240